Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
September 28, 2023 07:00 ET
|
Bolt Biotherapeutics, Inc.
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersThe FDA granted BDC-1001...
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
September 12, 2023 08:05 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
Bolt Biotherapeutics to Participate in September Investor Conferences
September 05, 2023 16:15 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023 16:10 ET
|
Bolt Biotherapeutics, Inc.
First patients dosed in the BDC-1001 Phase 2 programBDC-1001 Phase 1 data presented at ASCO 2023 demonstrated favorable safety profile and encouraging efficacy as a monotherapy and in combination with...
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
August 03, 2023 07:30 ET
|
Bolt Biotherapeutics, Inc.
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersBDC-1001 administered to initial...
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
July 31, 2023 17:27 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the...
Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
May 25, 2023 17:05 ET
|
Bolt Biotherapeutics, Inc.
Treatment with BDC-1001 at the recommended Phase 2 dose (RP2D) resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with...
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023 16:05 ET
|
Bolt Biotherapeutics, Inc.
Comprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, including RP2D, to be presented at ASCO 2023BDC-1001 Phase 2 program expected to initiate...
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
April 26, 2023 10:00 ET
|
Bolt Biotherapeutics, Inc.
Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trialsREDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage...
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 29, 2023 16:15 ET
|
Bolt Biotherapeutics, Inc.
Positive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safetyBDC-1001 advances into a...